Table II.
A breakdown of the cancer types and cancer type‐specific treatments included in analyses restricted by haematological cancer subtype.
| Subtype | n | Breakdown | Specific regimens investigated in this subtype |
|---|---|---|---|
| Lymphoma and WM | 333 | 27 Hodgkin lymphomas; 55 follicular lymphomas; 78 non‐follicular lymphomas; 18 MTNKs; 96 non‐Hodgkin lymphomas; 16 WM; 45 other mature lymphoid haematopoietic cancers | Chemotherapy (n = 137), targeted agents (n = 23), B‐cell treatment (n = 154) R‐CHOP (n = 58), and R‐VCP or R‐GVCP (n = 14) |
| ALL, AML and MDS | 97 | 17 ALL; 65 AML; 15 MDS | Chemotherapy (n = 45), azacytidine (n = 9), daunorubicin (n = 15), and targeted agents (n = 15), cytarabine (n = 23) |
| MM and plasmacytoma | 275 | Immunomodulatory drugs as a group and broken down into:75 receiving lenalidomide, 26 receiving thalidomide and 22 pomalidomide as part of their regimen [in 41 patients the exact immunomodulatory drug was unknown, chemotherapies (n = 33), targeted agents (n = 133), proteasome inhibitors as a group (n = 112) and, bortezomib (n = 64), ixazomib (n = 17) and carfilzomib (n = 42) separately, and daratumumab (n = 26)] | |
| CLL | 80 | Chemotherapy n = 5, targeted therapies [n = 21, 16 of which were on the BTK inhibitor, ibrutinib] | |
| CML and MPN | 36 | 22 CML; 14 MPN. (Four of the MPN patients have myelofibrosis, three have polycythaemia vera and seven have essential thrombocythemia) | Targeted agents n = 17, 16 were taking tyrosine kinase inhibitors (including bosutinib, imatinib, nilotinib, dasatinib and ruxolitinib) or chemotherapy (n = 10 patients, 8 on hydroxycarbamide) |
ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; BTK, Bruton’s tyrosine kinase; CLL, chronic lymphocytic leukaemia; CML, chronic myeloid leukaemia; MDS, myelodysplastic syndrome; MM, multiple myeloma; MPN, myeloproliferative neoplasms; MTNK, mature T/NK‐cell lymphomas; R‐CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone; R‐GVCP, Rituximab, gemcitabine, cyclophosphamide, vincristine and prednisolone; R‐VCP, rituximab, cyclophosphamide, vincristine and prednisolone; WM, Waldenström macroglobulinaemia.